A Randomised, Controlled, Blinded Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian H5 Influenza Vaccine in Adults

Trial Profile

A Randomised, Controlled, Blinded Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian H5 Influenza Vaccine in Adults

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs ADVAX (Primary) ; Influenza A virus H5N1 vaccines (Primary)
  • Indications Influenza A virus H5N1 subtype
  • Focus Adverse reactions
  • Sponsors Vaxine
  • Most Recent Events

    • 20 Nov 2017 Planned End Date changed from 1 Dec 2017 to 1 Nov 2018.
    • 20 Nov 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Dec 2017.
    • 20 Nov 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top